Divisional of U.S.S.N. 08/918,189

Filed: December 22, 2003

PRELIMINARY AMENDMENT

Express Mail Label No.: EL 717 747 309 US

Date of Deposit: December 22, 2003

In the claims

Please amend the claims as follows:

1-14. (canceled)

15. (currently amended) A method for promoting wound healing in a subject,

comprising administering to a subject a therapeutically effective amount of a composition

comprising an osteopontin derived chemotactic peptide and a a pharmaceutically-acceptable

carrier or diluent such that wound healing is promoted.

16-17. (canceled)

18. (currently amended) The method of claim 15, wherein said the therapeutic

composition is administered topically.

19-20. (canceled)

21. (currently amended) A method for promoting cell migration to a target site in a

subject comprising administering to a cell at the target site in said the subject a therapeutically

effective amount of an osteopontin derived chemotactic peptide for a time and under conditions

such that migration of said the cell to the target site is promoted, wherein the cell bears receptors

that recognize a peptide in the therapeutic composition.

22. (currently amended) A method for modulating inducing in vitro cellular

chemotaxis, comprising administering to incubating a cell in the presence of a therapeutically

effective amount of an osteopontin derived chemotactic peptide for a time and under conditions

3

CMCC 512 DIV 078856/00050 Divisional of U.S.S.N. 08/918,189

Filed: December 22, 2003

PRELIMINARY AMENDMENT

Date of Deposit: December 22, 2003

Express Mail Label No.: EL 717 747 309 US

effective to induce chemotaxis of the cell, wherein the cell bears receptors that recognize the

peptide such that modulation of cellular chemotaxis occurs.

23-25. (canceled)

26. (currently amended) A method for treating inhibiting the formation of

atherosclerotic plaques in a subject, comprising administering to a the subject a therapeutically

effective amount of an osteopontin derived chemotactic peptide, such that formation of

artherosclerotic atherosclerotic plaques is prevented.

27-28. (canceled)

29. (currently amended) A method of inducing either in vitro or in vivo chemotaxis

of a cell, comprising administering to a cell subject an osteopontin derived chemotactic peptide

for a time and under conditions in an amount effective to induce chemotaxis, wherein the cell

bears receptors that recognize the peptide.

30. (currently amended) The method of claim 29 22, wherein said the cell is a

mammalian cell.

31. (currently amended) The method of claim 29, wherein said the cell is selected

from the group consisting of a smooth muscle <u>cell</u> cells, a macrophage macrophages, an

endothelial <u>cell</u> cells, vascular cells and cancerous cells a vascular cell.

32-33. (canceled)

34. (new) The method of claim 22, wherein said the cell is selected from the group

consisting of a smooth muscle cell, a macrophage, an endothelial cell, and a vascular cell.

4

CMCC 512 DIV 078856/00050